Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Pertwee RG.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63. doi: 10.1098/rstb.2011.0381. Review.

2.

Emerging strategies for exploiting cannabinoid receptor agonists as medicines.

Pertwee RG.

Br J Pharmacol. 2009 Feb;156(3):397-411. doi: 10.1111/j.1476-5381.2008.00048.x. Review.

3.

Oxidative stress and cannabinoid receptor expression in type-2 diabetic rat pancreas following treatment with Δ⁹-THC.

Coskun ZM, Bolkent S.

Cell Biochem Funct. 2014 Oct;32(7):612-9. doi: 10.1002/cbf.3058. Epub 2014 Sep 3.

PMID:
25187240
4.

Endocannabinoids and Their Pharmacological Actions.

Pertwee RG.

Handb Exp Pharmacol. 2015;231:1-37. doi: 10.1007/978-3-319-20825-1_1. Review.

PMID:
26408156
5.

Latest advances in cannabinoid receptor agonists.

Thakur GA, Tichkule R, Bajaj S, Makriyannis A.

Expert Opin Ther Pat. 2009 Dec;19(12):1647-73. doi: 10.1517/13543770903436505. Review.

PMID:
19939187
6.

The pharmacology of cannabinoid receptors and their ligands: an overview.

Pertwee RG.

Int J Obes (Lond). 2006 Apr;30 Suppl 1:S13-8. Review.

PMID:
16570099
7.

Endocannabinoid System: A Multi-Facet Therapeutic Target.

Kaur R, Ambwani SR, Singh S.

Curr Clin Pharmacol. 2016;11(2):110-7. Review.

PMID:
27086601
8.

Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.

Deng L, Guindon J, Cornett BL, Makriyannis A, Mackie K, Hohmann AG.

Biol Psychiatry. 2015 Mar 1;77(5):475-87. doi: 10.1016/j.biopsych.2014.04.009. Epub 2014 Apr 25.

9.

Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond.

Pertwee RG.

Addict Biol. 2008 Jun;13(2):147-59. doi: 10.1111/j.1369-1600.2008.00108.x. Review.

PMID:
18482430
10.

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O.

ACS Chem Neurosci. 2012 May 16;3(5):400-6. doi: 10.1021/cn200114w. Epub 2012 Feb 9.

11.

Additive antiemetic efficacy of low-doses of the cannabinoid CB(1/2) receptor agonist Δ(9)-THC with ultralow-doses of the vanilloid TRPV1 receptor agonist resiniferatoxin in the least shrew (Cryptotis parva).

Darmani NA, Chebolu S, Zhong W, Trinh C, McClanahan B, Brar RS.

Eur J Pharmacol. 2014 Jan 5;722:147-55. doi: 10.1016/j.ejphar.2013.08.051. Epub 2013 Oct 22.

PMID:
24157976
12.

Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.

Davis MP.

Expert Opin Investig Drugs. 2014 Aug;23(8):1123-40. doi: 10.1517/13543784.2014.918603. Epub 2014 May 16. Review.

PMID:
24836296
13.

The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor.

Cox ML, Haller VL, Welch SP.

Eur J Pharmacol. 2007 Sep 10;570(1-3):50-6. Epub 2007 Jun 5.

PMID:
17588560
14.

Therapeutic potential of cannabinoid receptor ligands: current status.

Singh J, Budhiraja S.

Methods Find Exp Clin Pharmacol. 2006 Apr;28(3):177-83. Review.

PMID:
16810344
15.

Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties.

Cumella J, Hernández-Folgado L, Girón R, Sánchez E, Morales P, Hurst DP, Gómez-Cañas M, Gómez-Ruiz M, Pinto DC, Goya P, Reggio PH, Martin MI, Fernández-Ruiz J, Silva AM, Jagerovic N.

ChemMedChem. 2012 Mar 5;7(3):452-63. doi: 10.1002/cmdc.201100568. Epub 2012 Feb 2.

16.

Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain.

Bagüés A, Martín MI, Sánchez-Robles EM.

Eur J Pharmacol. 2014 Dec 15;745:69-75. doi: 10.1016/j.ejphar.2014.10.016. Epub 2014 Oct 19.

PMID:
25446925
17.

At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction.

Montecucco F, Di Marzo V.

Trends Pharmacol Sci. 2012 Jun;33(6):331-40. doi: 10.1016/j.tips.2012.03.002. Epub 2012 Apr 13. Review.

PMID:
22503477
18.

Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.

Calik MW, Carley DW.

Sleep. 2017 Sep 1;40(9). doi: 10.1093/sleep/zsx112.

19.

Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.

Mendizábal VE, Adler-Graschinsky E.

Br J Pharmacol. 2007 Jun;151(4):427-40. Epub 2007 Apr 23.

20.

The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.

Di Marzo V.

Pharmacol Res. 2009 Aug;60(2):77-84. doi: 10.1016/j.phrs.2009.02.010. Epub 2009 Mar 4. Review.

PMID:
19559360

Supplemental Content

Support Center